PLC Systems of Franklin, MA, plans to initiate clinical studies by 2007 for a new product designed to protect kidney function from the potentially harmful effects of contrast media.
Renal Guard is an automated, real-time fluid measurement and replacement system that is intended to prevent contrast-induced nephropathy (CIN) by matching a patient's urine output with normal saline in order to keep a patient hydrated during an interventional cardiology or radiology procedure.
PLC plans to initiate a U.S. pilot feasibility study later this year, and clinical trials in 2007. The company has a commercial launch target of late 2008 or early 2009, pending regulatory clearance.
By AuntMinnie.com staff writers
September 15, 2006
Related Reading
Assessing patient risk will help prevent contrast-induced nephropathy, June 15, 2006
Firm raises eyebrows with push to enforce antikidney-failure patent, June 13, 2006
GE investigates Omniscan cases, June 12, 2006
Part II: Palliative steps prevent contrast-induced nephropathy, September 20, 2005
Part I: Identifying patients at risk of contrast-induced nephropathy, September 13, 2005
Copyright © 2006 AuntMinnie.com
